BOSTON,
Nov. 11, 2014 /
PRNewswire/
-- AbbVie (NYSE:ABBV) announced detailed results from its open-label
Phase 2b study, PEARL-I, which demonstrated that 100 percent of
genotype 4 (GT4) patients who were new to therapy (n=42/42) or who had
failed previous treatment with pegylated interferon (pegIFN) and RBV
(n=49/49) achieved sustained virologic response rates at 12 weeks
post-treatment (SVR
12) after taking AbbVie's investigational
treatment with ribavirin (RBV). Additionally, 90.9 percent of patients
who were new to therapy achieved SVR
12 (n=40/44) after
taking the treatment without RBV. These data will be presented today
during a poster session at The Liver Meeting® 2014.